Evidence map›Paper›PMID 39446179›Full record

SynthesisEuropean journal of clinical pharmacology2025

Use of dipyrone during pregnancy and risk of congenital anomalies: a systematic review.

Karine Duarte Curvello, Helana Ortiz Garcia, Tatiana da Silva Sempé, Raimunda Alyne Maciel Feitosa da Silva, Luana Giongo Pedrotti, Fernanda Sales Luiz Vianna, Tatiane da Silva Dal Pizzol

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in European journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Karine Duarte CurvelloPrograma de Pós-Graduação Em Assistência Farmacêutica, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.ORCID http://orcid.org/0000-0002-9199-7533
Helana Ortiz GarciaInstituto Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.ORCID http://orcid.org/0000-0002-9163-998X
Tatiana da Silva SempéPrograma de Pós-Graduação Em Assistência Farmacêutica, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.ORCID http://orcid.org/0000-0001-9906-3842
Raimunda Alyne Maciel Feitosa da SilvaHospital Moinhos de Vento, Porto Alegre, RS, Brazil.ORCID http://orcid.org/0009-0002-4224-1403
Luana Giongo PedrottiHospital Moinhos de Vento, Porto Alegre, RS, Brazil.ORCID http://orcid.org/0000-0001-9755-9019
Fernanda Sales Luiz ViannaDepartamento de Genética, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.ORCID http://orcid.org/0000-0001-6339-4869
Tatiane da Silva Dal PizzolPrograma de Pós-Graduação Em Assistência Farmacêutica, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil. tatiane.silva@ufrgs.br.ORCID http://orcid.org/0000-0002-7566-7745

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed to summarize the evidence on the teratogenic effects of dipyrone used during pregnancy.

methodsDatabases (MEDLINE, EMBASE, Cochrane Library, CINAHL, Web of Science, Lilacs, SciELO, SCOPUS, OasisBR, and OpenGray) were reviewed until September 2023. We included studies that compared pregnant women who used dipyrone during any gestational period with those who used other analgesics or did not use any analgesics during the same gestational period. The outcome assessed was the presence of any congenital anomaly. Two reviewers independently conducted the review process, and a third reviewer resolved any disagreements. The risk of bias was assessed using the Joanna Briggs Institute tool for observational studies. The reviewed data synthesis is presented in narrative form.

resultsThe search retrieved 2045 results, of which seven studies were included in the review, four were case‒control studies, and three were cohort studies involving 153,562 participants. The congenital anomalies evaluated varied across studies, with unspecified congenital anomalies predominating. Five of seven studies found no association between dipyrone and congenital anomalies. In a case‒control study, a positive association was found between dipyrone use and isolated congenital cataracts compared to two control groups; in another study, a positive association for unspecified congenital anomalies was observed in only one of the two control groups analyzed. In all studies, a high risk of bias was identified, especially regarding measuring the exposure, outcome, and assessment of confounding factors.

conclusionThere is not enough evidence to define the risk of congenital anomalies associated with dipyrone use during pregnancy. REGISTRATION: CRD 42022333041.

Indexed as

Abnormalities, Drug-InducedAnti-Inflammatory Agents, Non-SteroidalDipyroneCongenital AbnormalitiesFemaleHumansPregnancyAnti-Inflammatory Agents, Non-SteroidalDipyroneCongenital anomaliesDipyroneObservational studiesPregnancySystematic review

Identifiers

PMID39446179

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.